A biopharmaceutical company developing eyedrop treatment for Age Related Macular Degeneration wet AMD using VEGF alternative splicing.
Location: United Kingdom, England, Duxford
Total raised: $6.11M
Investors 7
| Date | Name | Website |
| - | o2h ventur... | o2hventure... |
| - | Angel CoFu... | acfinvesto... |
| - | BioCity | biocity.co... |
| - | Cambridge ... | cambridgea... |
| - | Parkwalk A... | parkwalkad... |
| - | Stoic VC | stoicvc.co... |
| - | Martlet | martletcap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.02.2017 | - | $6.11M | - |
Mentions in press and media 8
| Date | Title | Description |
| 15.07.2026 | Exonate appoints Olav Hellebø as Chief Executive Officer | - |
| 12.03.2024 | Exploristics and Exonate announce successful collaboration to enhance clinical trial study design using cloud-based simulation | Exploristics’ cloud-based simulation platform KerusCloud used to enhance study design for Exonate’s upcoming Phase IIb study following successful Phase Ib/IIa study Cambridgeshire and Belfast, UK: Exploristics, a world-leading provider of b... |
| 29.11.2023 | Exonate diabetic macular oedema asset passes phase Ib/2a challenge | - |
| 28.11.2023 | Exonate announces successful completion of Phase Ib/IIa trial in diabetic macular oedema | Cambridgeshire and Nottingham, UK, 28 November 2023: Exonate Ltd., an mRNA therapy company focused on treatments for diabetic complications, announces its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in a phase ... |
| 08.03.2019 | Top 21 #OnetoWatch recognition reflects the range of innovation across the East of England | Top 21 #OnetoWatch recognition reflects the range of innovation across the East of England 08-03-2019 Cofinitive is delighted to announce the Top 21 in its #OnetoWatch campaign, recognised at the inaugural event hosted at The Bradfield Cent... |
| 06.02.2017 | Exonate Receives £4.9M Award by Wellcome Trust | Exonate, a Cambridge, UK-based early stage biotechnology company, received a £4.9m Seeding Drug Discovery award by the Wellcome Trust. The company – which recently closed a £1.5m funding round from new and existing shareholders – will use t... |
| - | Exonate – University of Bristol Enterprise Fund II investment | We are delighted to announce that the University of Bristol Enterprise Fund II, managed by Parkwalk, has invested in Exonate. |
| - | Exonate – University of Bristol Enterprise Fund I investment | We are delighted to announce that the University of Bristol Enterprise Fund I, managed by Parkwalk, has invested in Exonate. |